ERIS Lifesciences Ltd

ERIS Lifescience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

ERIS Lifesciences Ltd

₹ 1,355 -1.49%
31 Jul - close price
eris.co.in BSE: 540596 NSE: ERIS
About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Key Points

Market Position
The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market. [1]

Website BSE NSE
  • Market Cap ₹ 18,773 Cr.
  • Current Price ₹ 1,355
  • High / Low ₹ 1,856 / 1,200
  • Stock P/E 91.0
  • Book Value ₹ 231
  • Dividend Yield 0.54 %
  • ROCE 11.1 %
  • ROE 8.89 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 56.8%

Cons

  • Stock is trading at 5.87 times its book value
  • The company has delivered a poor sales growth of 10.4% over past five years.
  • Company has a low return on equity of 8.09% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
411 410 324 341 457 437 400 405 579 650 315 277 444
256 265 250 262 333 294 300 284 362 354 238 256 324
Operating Profit 156 144 74 79 123 143 100 121 216 297 77 22 120
OPM % 38% 35% 23% 23% 27% 33% 25% 30% 37% 46% 25% 8% 27%
4 7 3 20 5 6 8 17 23 24 10 27 26
Interest 7 7 15 29 56 56 55 53 45 46 45 43 42
Depreciation 20 25 28 29 46 46 47 43 38 39 39 39 40
Profit before tax 133 120 35 42 27 46 6 41 156 235 4 -33 64
Tax % 16% 2% 9% 5% 36% 39% 70% 26% 36% 36% 21% -74% 25%
111 118 32 40 17 28 2 30 100 150 3 -9 48
EPS in Rs 8.14 8.66 2.33 2.90 1.25 2.06 0.13 2.24 7.34 10.98 0.23 -0.62 3.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
548 605 713 761 897 1,020 1,109 1,216 1,331 1,487 1,698 1,822 1,687
437 435 442 445 562 661 691 727 825 1,031 1,210 1,209 1,171
Operating Profit 111 171 271 316 334 359 417 488 506 456 487 612 516
OPM % 20% 28% 38% 42% 37% 35% 38% 40% 38% 31% 29% 34% 31%
7 3 25 28 32 11 10 25 16 33 35 84 87
Interest 0 0 1 10 23 2 1 3 21 57 220 180 177
Depreciation 15 20 21 22 32 45 38 51 65 102 182 154 157
Profit before tax 103 154 274 312 312 324 389 459 437 329 120 362 270
Tax % 19% 10% 9% 6% 8% 10% 10% 9% 9% 9% 36% 33%
83 138 248 294 285 291 351 417 398 300 77 244 192
EPS in Rs 6,060.36 10,034.18 18.05 21.36 20.75 21.45 25.82 30.69 29.27 22.03 5.68 17.62 14.08
Dividend Payout % 0% 61% 0% 0% 0% 13% 21% 20% 25% 0% 129% 41%
Compounded Sales Growth
10 Years: 12%
5 Years: 10%
3 Years: 11%
TTM: -7%
Compounded Profit Growth
10 Years: 6%
5 Years: -6%
3 Years: -14%
TTM: 29%
Stock Price CAGR
10 Years: %
5 Years: 12%
3 Years: 19%
1 Year: -25%
Return on Equity
10 Years: 18%
5 Years: 12%
3 Years: 8%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.14 0.14 14 14 14 14 14 14 14 14 14 14
Reserves 267 305 561 854 1,142 1,286 1,562 1,905 2,208 2,510 2,501 3,182
1 0 0 376 176 0 0 0 317 2,572 2,245 2,101
86 96 82 126 138 183 179 232 245 254 463 481
Total Liabilities 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 5,350 5,222 5,778
61 65 92 490 484 601 584 642 898 1,516 2,412 2,353
CWIP 0 0 0 0 3 4 2 3 0 1 0 0
Investments 182 206 381 546 580 320 531 778 997 1,619 991 1,414
110 131 184 335 403 558 638 728 889 2,214 1,819 2,011
Total Assets 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 5,350 5,222 5,778

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
92 133 210 236 216 265 395 369 322 336 702 564
-94 -45 -199 -593 2 127 -348 -268 -513 -2,492 -359 -694
1 -84 -18 363 -221 -334 -81 -88 194 2,160 -310 71
Net Cash Flow -1 4 -6 7 -2 58 -34 13 3 4 32 -59
Free Cash Flow 79 109 161 212 180 121 370 317 11 -13 694 515
CFO/OP 104% 96% 97% 96% 86% 88% 111% 93% 79% 90% 147% 104%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 16 15 21 29 31 50 37 41 63 59 51 62
Inventory Days 181 156 161 194 206 145 119 155 98 119 140 71
Days Payable 121 88 86 266 207 200 159 177 128 143 158 128
Cash Conversion Cycle 75 84 97 -43 30 -4 -3 19 33 35 33 4
Working Capital Days 13 8 31 2 -22 58 65 80 52 -413 -99 -145
ROCE % 44% 53% 62% 35% 26% 24% 27% 27% 20% 10% 7% 11%

Insights

In beta
Mar 2017 Mar 2018 Mar 2019 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
In-house Manufacturing Share (Guwahati)
%

Log in to view insights

Please log in to see hidden values.

Login
Chronic and Sub-Chronic Share of Revenue
%
IPM Rank in Indian Pharmaceutical Market
rank
Diabetes Care Share of Revenue
%
Field Force (Medical Representatives)
number
Overall Insulins Market Share
%
RHI Cartridges Market Share
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
54.91% 54.90% 54.90% 54.88% 54.87% 54.86% 54.85% 54.83% 54.85% 54.85% 53.92% 54.14%
13.20% 13.13% 14.27% 14.59% 8.01% 8.36% 8.43% 8.39% 7.21% 6.85% 6.39% 5.76%
14.52% 14.55% 15.63% 16.23% 18.64% 18.07% 18.07% 18.18% 19.36% 20.31% 20.35% 20.71%
17.37% 17.41% 15.20% 14.30% 18.47% 18.73% 18.64% 18.59% 18.57% 17.97% 19.33% 19.39%
No. of Shareholders 42,24546,49651,75344,17646,34653,31450,08752,22559,43854,71351,65650,798

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls